By targeting the dysregulated PI3K pathway, these inhibitors effectively interfere with communication between the PI3K pathway and hormone receptor signaling, allowing HR+ BC cells to respond to antiestrogenic drugs such as tamoxifen [155]. Here, NR4A1 is linked to breast cancer.